Redox Biol 46:102122 Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gmez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN, NAFLD Nomenclature consensus group (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Global Health Data Exchange (GHDx), ( (accessed November 12, 2023)
CodY is a global transcriptional regulator required for virulence in group B streptococcus
This minor modification: Increases binding affinity at the IGF-1 receptor by up to 10x Makes the peptide unaffected by IGFBPs , allowing near-immediate receptor activation Reduces half-life to 2030 minutes , creating a fast-acting but short-lived effect Because of its rapid uptake and potency, IGF-1 DES is ideal for: Localized muscle growth (spot injections into lagging muscles) Injury rehabilitation and connective tissue repair Use immediately post-workout to amplify the muscle-building response in trained muscle groups IGF-1 DES is particularly effective in targeting damaged tissue due to its high receptor affinity and localized activity. Bach, Current Pharmaceutical Design Benefits Comparison: IGF-1 LR3 vs IGF-1 DES Both IGF-1 analogs deliver impressive anabolic resultsbut the key to maximizing their effects lies in knowing when and how to use each
